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Commitment of HT29-18 cells to enterocyte-like differentiation by glucose removal is related to a decreased 
capacity to generate CAMP after treatment with vasoactive intestinal peptide (VIP), forskolin or sodium 
fluoride. In contrast, the potency of VIP (EC,,= 1 .l - 1.3 x lo-lo M) and the pharmacological specificity 
of the VIP receptor (VIP > rh GRF l-43 > PHI > secretin) are unchanged uring differentiation and retrodif- 
ferentiation. These results indicate that disturbances in VIP receptor - post-receptor activity, involving cell 
surface VIP receptors, membrane and intracellular transducers of hormonal information, occur during 
enterocyte-like differentiation of the HT29- 18 subclone. 
HT29-18 subclone Enterocyte-like dyferentiation 
1. INTRODUCTION 
Villus formation in the stratified epithelium of 
the fetal human small intestine at 8-9 weeks gesta- 
tion is followed by the morphological and bio- 
chemical differentiation of the absorptive cells at 
9-10 weeks gestation [l-3]. Histogenesis and mor- 
phogenesis of the intestine coincides with the 
development of the highly organized microvillus 
structure at the apical cell surface and with the ap- 
pearance of many brush border enzymes in the ab- 
sorptive cells [ 1,2]. Several investigations have 
documented the biological and biochemical actions 
of the vasoactive intestinal peptide (VIP) in the 
mature intestine [4]. They include net fluid and 
electrolyte secretions [5-71, receptor binding and 
adenylate cyclase activation in normal [8,9] and 
cancerous HT-29 intestinal cells [lo]. We have 
characterized specific and functional VIP recep- 
tors in small intestinal epithelial cells isolated from 
human fetuses at 18-23 weeks gestation [ll], and 
in intestinal villi isolated from rat fetuses at 19 
VIP receptor activity Adenylate cyclase Forskolin 
days gestation [12,13]. At this stage of develop- 
ment, rat intestine exhibits an antero-posterior gra- 
dient of differentiation; thus, villus structures are 
well organized in the duodenum, and the lower 
part of the small intestine exhibited epithelial pro- 
jections and a linear basal membrane [ 141. 
For further investigation of plasma membrane 
development and cell surface receptor expression 
during the maturation of intestinal cells, [l l-131 
we evaluated VIP receptor activity during entero- 
cyte-like differentiation and retrodifferentiation of 
the HT29-18 human colonic cancerous subclone 
[ 151. These cultured clonal cells can be primed for 
differentiation into enterocyte-like cells in glucose- 
free medium containing 5 mM galactose (glucose 
removal) and dedifferentiated following subse- 
quent substitution of galactose for glucose, as 
described in the noncloned HT-29 cell line 1161. 
Here we therefore measured VIP receptor activity 
in clonal and nonclonal HT-29 cells (i.e. cell CAMP 
generation and adenylate cyclase activation) and 
examined by electron microscopy the ultrastruc- 
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tural characteristics of HT29-18 cells cultured in a 
medium containing glucose or galactose. VIP 
receptor specificity was evaluated in undifferen- 
tiated and enterocyte-like HT29- 18 cells incubated 
in the presence of VIP and of its 5 natural 
analogues: secretin, pancreatic glucagon, peptide 
having N-terminal histidine and C-terminal 
isoleucine amide (PHI), rat hypothalamic growth 
hormone releasing factor l-43 (rh GRF l-43) and 
gastric inhibitory peptide (GIP). Results were com- 
pared to those obtained with the ubiquitous 
adenylate cyclase activators sodium fluoride and 
forskolin. Part of this work has been published as 
an abstract [17]. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
The undifferentiated and differentiated HT29-18 
human colonic cancerous subclone, generously 
provided by Dr D. Louvard (Unite de Biologie des 
Membranes, Institut Pasteur, 75724 Paris) was 
cultured in Dulbecco’s modified Eagle medium 
supplemented with either 25 mM D-glucose (undif- 
ferentiated cells) or 5 mM D-galactose (differen- 
tiated cells), plus lO(?‘o dialyzed fetal bovine serum, 
as described in [ 15,161. Differentiation of HT29-18 
cells was induced by gradual substitution of 
glucose for galactose in the culture medium by a 
daily increment of 20% for 5 consecutive days. 
Thereafter, cells were passaged 25 times and main- 
tained in galactose-rich medium for 1 year. Retro- 
differentiation was induced by returning the 
enterocyte-like HT29-18 cells to glucose medium 
for 5 days. Cells were then passaged at a starting 
density of 6 x lo6 cells per 75 cm’ plastic flask and 
cultured for l-2 weeks in 25 mM glucose-rich 
medium before experimentation. The glucose-rich 
medium was changed daily, and the galactose-rich 
medium, every 48 h. 
The HT-29 cell line was kindly provided by Dr 
J. Fogh (Sloan Kettering Institute, NY) and 
cultured by the standard method described [18]. 
Between passages 26 and 34 in glucose-rich medium 
and between passages 30 and 36 in galactose-rich 
medium, HT29-18 cells were washed 3 times at 
37°C with magnesium and calcium-free phosphate- 
buffered saline and removed from culture flasks 
after exposure to 0.02% EDTA. The isolated cells 
were washed 3 times at 20°C with 40 ml Krebs- 
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Ringer phosphate buffer (pH 7.4) and resuspended 
after centrifugation at 2OOxg for 3 min in 35 mM 
Tris-HCI buffer containing 1.4% bovine serum 
albumin (BSA) and 50 mM NaCl, (pH 7.5). Cell 
viability determined by trypan blue exclusion was 
about 80-95%. 
2.2. Cell morphology 
For ultrastructural examination, HT29- 18 cells 
were harvested from culture flasks with a rubber 
policeman and fixed for 1 h at 4°C in 2% (v/v) 
glutaraldehyde in 0.1 M cacodylate buffer (pH 
7.2). This material was then rinsed overnight in the 
same buffer and postfixed in 1% osmium tetroxide 
for 3 min at room temperature [ 191. The pellet was 
then dehydrated and embedded in Epon 812. 
Ultrathin sections were obtained on an ultracut 
Reichert microtome. After double staining with 
uranyl acetate and lead citrate, the sections were 
examined in a Zeiss Em 109 electron microscope 
operated at 55 kV. 
2.3. Cellular CAMP generation 
In a standard assay, 150~1 of the cell suspension 
(0.2-0.5 x lo6 cells) was preincubated for 10 min at 
37°C with or without the CAMP phosphodiesterase 
inhibitor isobutylmethylxanthine (IBMX) (1.2 
mM), and in 250 ~1 Tris-HCl buffer containing 
1.4% BSA and 50 mM NaCl (pH 7.5). The reac- 
tion was initiated by adding 100~1 of appropriate 
hormones or chemicals, and was stopped at the 
time indicated by adding 50~1 HC104. CAMP was 
determined by the radioimmunoassay method 
detailed in [20]. The absolute values are expressed 
as pmol CAMP produced by lo6 clonal and non- 
clonal HT-29 cells. 
2.4. Adenylate cyclase preparation and assay 
Undifferentiated and enterocyte-like HT29-18 
cells were disrupted at 4°C by 3 bursts of 10 s each 
(15 x lo6 cells/ml) with a Polytron homogenizer 
(Kinematica, Luzern, Switzerland) in 10 mM Tris- 
HCl buffer (pH 7.5) containing 1 mM EDTA, 30 
mM NaCl, 1 mM dithiothreitol and 5 PM PMSF. 
The crude plasma membrane preparation was ob- 
tained by centrifugation (27 000 x g, 30 min at 4°C) 
in a Sorvall centrifuge RC-2 (Newton, CT). 
Adenylate cyclase activity was measured just after 
centrifugation by a modified version of the method 
in [ll]. The reaction was initiated by addition of 
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the membrane-bound adenylate cyclase (15-20 pug 
membrane protein per tube) and the mixture in- 
cubated at 30°C for 10 min. Data are expressed in 
pmol CAMP produced/min per mg membrane pro- 
tein. 
2.5. Expression of results 
Results are presented as means + SE. The signifi- 
cance of the differences observed was assessed by 
Student’s t-test. Regression lines were fitted to the 
linear portions of the dose-response curves derived 
from individual experiments. The apparent ECso 
potencies, i.e. the doses required to produce half- 
maximal stimulation by the peptides, were calcu- 
lated by the least square method. All calculations 
were performed on an HP-85 microcomputer 
(Hewlett-Packard). 
2.6. Peptides and chemicals 
Highly purified natural porcine VIP and PHI 
were purchased from Professor V. Mutt (GHI 
Laboratory, Stockholm, Sweden). Crystallized, 
highly purified porcine glucagon (lot 42306) was 
from Novo Research Institute (Bagsvaerd, Den- 
mark). Synthetic porcine secretin and rat hypo- 
thalamic GRF l-43 were prepared by Professor E. 
Wiinsch (Max Planck Institut fur Peptidchemie, 
Martinsried, FRG) and Dr J. Rivier and Dr W. 
Vale (Salk Institute, San Diego, CA) respectively. 
Forskolin, sodium fluoride, dithiothreitol, phenyl- 
methyl sulfonyl fluoride (PMSF), GTP, pure 
ATP, CAMP and IBMX were from Sigma (St. 
Louis, MO). Na’? was from the Radiochemical 
Centre (Amersham, England). 
3. RESULTS 
3.1. Morphological characteristics ofHT29-18 cells 
As shown in fig. 1 (left), undifferentiated HT29- 
18 cells grow as disorganized multilayers and 
display an unpolarized nucleus as well as cyto- 
plasmic projections randomly dispersed all round 
the cell periphery. Enterocytic-like HT29-18 cells 
have a reduced nuclear/cytoplasmic ratio and ex- 
hibit typical brush border structures composed of 
microvilli at their apical surface (fig.1, middle). 
The microfilaments of the microvillus core extend 
deep into the cytoplasm (fig.1, right). In these 
Fig. 1. Ultrastructural appearance of undifferentiated and enterocyte-like HT29-18 cells. Left panel: transmission elec- 
tron microscopy of undifferentiated cells growing as poorly organized epithelial layers in culture flasks. The population 
doubling time was 19 h in glucose-rich medium (n, nucleus; c, cytoplasmic projections; bar, 5 PM). Middle panel: 
transmission electron microscopy of enterocyte-like cells growing as polarized monolayers. The population doubling 
time was 52 h in galactose-rich medium (b, brush border; i, interdigitations, barr, 5 PM). Right panel: enlargement of 
the microvillus structure located at the apical surface of enterocyte-like cells (mf, microfilaments; mv, microvillus; bar, 
1 pm). 
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cells, apical junctional complexes, including tight 
jucntions and desmosomes, have often been 
observed [ 171. 
3.2. Kinetics of VIP receptor activity 
As shown in fig.2 (expts 1 and 2), cellular CAMP 
levels were 1.4 Z!Z 0.1 and 2.3 f 0.3 pmol/106 cells in 
nonclonal and clonal HT-29 cells, respectively, in- 
cubated for 10 min at 37”C, in the absence of the 
phosphodiesterase inhibitor IBMX (n = 16-24 
determinations). After the addition of 1O-8 M 
VIP, the concentration of CAMP rose within 30 s; 
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Fig.2. Effect of time and IBMX on VIP receptor activity 
in HT-29 cells and in the HT29-18 subclone cultured in 
glucose- or galactose-rich medium. Cyclic AMP genera- 
tion was evaluated under basal (0) or stimulated condi- 
tions [10m8 M VIP (0) and 2x 10-j M forskolin (A)] in 
cells incubated at 37”C, either in the absence of IBMX 
(expt 1, noncloned HT-29 cells; expt 2, undifferentiated 
HT29-18 cells; expt 3, enterocyte-like cells, and expt 5, 
retrodifferentiated cells), or in the presence of 1.2 mM 
IBMX (expt 4, enterocyte-like cells, and expt 6, retrodif- 
ferentiated cells). Data are means -+ SE from 3-5 ex- 
periments performed in duplicate or triplicate. 
half-maximal and maximal stimulations were 
respectively observed within 45 s and 2 min in 
HT-29 cells and within 60 s and 5 min in the 
HT29-18 subclone. Maximal CAMP stimulation by 
VIP over basal levels represented a70-fold increase 
(98 k7.5 pmol/106 cells) and a 17-fold increase 
(4Ok3.6 pmol/106 cells) in HT-29 and HT29-18 
cells respectively. In both types of cells, basal and 
VIP-stimulated CAMP levels remained constant 
for the remainder of the 10 min incubation. A very 
different picture was seen in the enterocytic-like 
cells (fig.2, expt 3). In this system, VIP produced 
a 3-fold increase in CAMP generation after 30 s 
(from 1.5 + 0.1 to 4.8 +0.5 pmol/106 cells), fol- 
lowed by a rapid decline in CAMP levels which 
returned to basal values at 2 min. CAMP produc- 
tion (4.8 + 0.6 pmol/106 cells) remained far above 
the basal level for 10 min. However, in the 
presence of 2 x 10T5 M forskolin, in retrodifferen- 
tiated cells (fig.2, expt 5), CAMP levels reached a 
peak value at 1 min in the presence of VIP, rising 
from 1.9+ 0.3 to 48 + 2.8 pmol/106 cells (i.e. a 
25-fold increase), decreased to 15 + 0.5 pmol at 3 
min, and remained far above the basal level for the 
subsequent 7 min of incubation. 
Similarly, after forskolin treatment, erythro- 
cytic-like differentiation and retrodifferentiation 
of the HT29-18 subclone was associated with re- 
duced CAMP accumulation. In HT29-18 cells in- 
cubated for 10 min at 37°C in the absence of 
IBMX, the CAMP levels measured in the presence 
of 2 x lo-’ M forskolin declined from 40 k 2 pmol 
in the undifferentiated cells (expt 2) to 4.8 kO.6 
pmol in the enterocyte-like cells (expt 3), and to 
21 +: 3pmol in the retrodifferentiated cells (expt 5). 
Addition of the phosphodiesterase inhibitor 
IBMX during incubation of differentiated and 
retrodifferentiated HT29-18 cells fully restored 
(expt 4) or increased (expt 6) the CAMP production 
capacity previously measured in undifferentiated 
cells after addition of VIP (expts 1 and 2). Under 
these conditions, CAMP levels in differentiated 
HT29-18 cells rose from the basal levels of 1.8 f 0.2 
to 5Ort 12 pmol/106 cells (27-fold increase, expt 4), 
and in retrodifferentiated cells from 3.78 + 0.3 to 
31Ok27 pmol/106 cells (80-fold increase, expt 6). 
3.3. Adenylate cyclase activity 
After the addition of lo-* M VIP, adenylate 
cyclase activity in undifferentiated HT29-18 cells 
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Table 1 
Effect of VIP and sodium fluoride on adenylate cyclase activity in undifferentiated 
and enterocytic-like HT29-18 cells 
Substance Dose Adenylate cyclase activity 
None 
NaF 
VIP 
Undifferentiated cells Enterocyte-like cells 
pmol/min per S-B/B pmol/min per S-B/B 
mg protein mg protein 
_ 55 + 8 260 + 60 
lo-’ M 645 f 130 10.7 + 1.2 1745 * 400 5.7 + 1.2* 
lo-’ M 365 + 80 5.7 f 1 770 + 210 1.9 + os* 
Absolute values (pmol/min per mg protein) and average -fold stimulation over 
basal adenylate cyclase activity (S-B/B) are means + SE from 5 (differentiated 
HT29-18 cells) to 6 different membrane preparations (undifferentiated HT29-18 
cells). Each assay was performed in duplicate. Significantly different at p<O.OS* 
from the corresponding control value 
increased from 55 + 8 to 365 + 80 pmol/min per mg 
protein i.e. a 5.7-fold rise in relation to the paired 
basal values (table 1). In enterocyte-like cells, the 
average stimulation by VIP dropped to a factor of 
1.9 *OS. The same applied to adenylate cyclase 
stimulation by fluoride in undifferentiated and 
enterocyte-like cells, i.e., 10.7-fold vs 5.7-fold 
increase. 
3 A. Potency of VIP and pharmacological 
specificity of the VIP receptor 
The pharmacological specificity of the VIP 
receptor during enterocyte-like differentiation and 
retrodifferentiation of the HT29- 18 subclone was 
established towards the relative potencies of VP 
and of its natural analogues as follows: VIP>rh 
GRF l-43> PHI> secretin (fig.3). Glucagon and 
[ Peptides], -log M 
11 10 9 8 7 6 
Fig.3. Pharmacological specificity of VIP receptor activity during enterocyte-like differentiation and retrodifferentia- 
tion of the HT29-18 subclone. Undifferentiated (expt l), differentiated (expt 2) and retrodifferentiated cells (expt 3) 
were incubated at 37°C for 5 min in the presence of 1.2 mM IBMX and of various concentrations of VIP (0) and of 
its analogues: rh GRF l-43 (0), PHI (A), secretin (0), pancreatic glucagon (v) and GIP (m). Basal CAMP levels (0). 
Results are means + SE from 3-6 experiments performed in duplicate (expts 1 and 2). Individual experiments from 
duplicate determinations are illustrated in expts 1 and 3. 
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GIP were inactive. Similarly, VIP potency in the 3 
cell types was unchanged; at 1.3 f 0.3 x lo-” M in 
HT29-18 cells, 1.1+0.2x 10-i’ M in enterocyte- 
like cells and 1.2 x lo-” M VIP in retrodifferen- 
tiated HT29-18 cells. 
4. DISCUSSION 
The basic finding of this work indicates that 
enterocyte-like differentiation of the human col- 
onic HT29-18 subclone corresponds to a decreased 
capacity of the differentiated cells to generate 
CAMP after forskolin treatment and cell surface 
receptor activation by VIP. We previously ob- 
tained very similar results in normal intestinal cells 
isolated from fetal and neonatal rats [12,17]. In 
this model, VIP produced marked persistent 
stimulation for 10 min in villous cells isolated from 
fetal rats at 19 days of gestation. This stimulation 
was transient in 5 day-old rats and undetectable in 
adults. Retrodifferentiation of HT29-18 enterocyte- 
like cells after substitution of galactose for glucose 
partly reversed this process, suggesting that retro- 
differentiated cells return to an intermediary stage 
in their programme of differentiation and dedif- 
ferentiation induced by the glucose-galactose 
balance in the culture medium. Accordingly, 
Louvard et al. [15] previously observed that the 
biosynthesis and storage of villin was lo-times 
higher in enterocyte-like cells than in the undif- 
ferentiated HT29-18 subclone, whereas villin levels 
remained high in retrodifferentiated cells. Further, 
in noncloned HT-29 cells, Pinto et al. [16] showed 
that the differentiation process was reversible for 
maltase, sucrase and aminopeptidase activity but 
not for alkaline phosphatase which stayed high. In 
this work, electron microscope examination reveal- 
ed that retrodifferentiated cells assume the mor- 
phological characteristics of partially dedifferen- 
tiated enterocyte-like HT29-18 cells (not shown). 
In contrast, the potency of VIP and the phar- 
macological properties of the VIP receptor were 
remarkably similar in all 3 cell types. The struc- 
tural requirements of the VIP receptor for adeny- 
late cyclase activation therefore remained un- 
changed during HT29-18 cell differentiation and 
retrodifferentiation. In this connection, we recent- 
ly reported that VIP receptors in small intestine 
epithelial cells isolated from human fetuses at 
18-23 weeks gestation and from rat fetuses at 19 
202 
days gestation are pharmacologically similar 
(VIP> PHI> secretin) to those characterized in 
mature intestine [ 1 l-131. We also made the same 
observation [19] for the secretin receptor in fundic 
and antral glands isolated during rat development, 
from the fetal to adult age stages (secretin> PHI, 
VIP). 
These variations in VIP receptor activity ob- 
served here during intestinal cell differentiation in 
the HT29-18 subclone and previously in the 
developing rat [12] might be due to changes in the 
following biochemical and physical parameters: 
the number, desensitization, internalization and 
turnover of VIP receptors, plasma membrane 
fluidity, adenylate cyclase pools, activity of the N, 
and N, subunits, CAMP phosphodiesterase activity 
(CAMP-PDE), or a combination of these para- 
meters. In agreement with this hypothesis, we 
recently demonstrated that VIP can down-regulate 
its own receptors [21,22] after short- or long-term 
VIP treatment of noncloned HT-29 cells and 
HGT-1 human gastric cells (desensitization). The 
equilibrium conditions obtained here in undif- 
ferentiated cells after addition of VIP are due to 
the balance between CAMP generation and degra- 
dation (fig.2, expts 1 and 2). The finding that addi- 
tion of IBMX fully restored VIP receptor activity 
suggests that CAMP-PDE activities changed during 
differentiation and retrodifferentiation. In this 
connection, Mangeat et al. [23] reported rapid 
specific activiation within 1 min of the low Km 
CAMP-PDE in noncloned HT-29 cells incubated at 
37°C with VIP (10-10-10-8 M). From the com- 
parative kinetic data for CAMP generation after 
VIP and forskolin, it is therefore likely that both 
receptor desensitization and CAMP-PDE activa- 
tion coincide with the transient rise in CAMP levels 
evoked by VIP in enterocyte-like cells incubated in 
the absence of IBMX (fig.2, expt.3). Secondly, it 
has been shown that the physical state of the 
plasma membrane (lipid microviscosity) may pro- 
mote inhibition or stimulation by a hormone via 
either the Ni or the N, structures of the cyclase 
[24]. For example, Robberecht et al. [25] have 
shown that short-chain alcohols inhibited for- 
skolin-stimulated rat cardiac adenylate cyclase, 
probably by interacting with lipids and altering 
membrane fluidity. It has been proposed in dif- 
ferent systems that forskolin acts directly on the 
catalytic unit C of the cyclase and also on the 
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mechanisms coupling this unit with the guanine 
nucleotide sites N, and Ni [26-291. In the case of 
the intestine, changes in lipid composition and 
membrane fluidity have been reported in the 
developing rat [30] and rabbit [31]. It is therefore 
tempting to speculate that enterocyte-like differen- 
tiation of the HT29-18 clone might be connected 
with some functional defect between the catalytic 
subunit andd its regulatory proteins. In agreement 
with this proposition, we have demonstrated here 
that the extent of stimulation of adenylate cyclase 
activity after VIP and sodium fluoride dropped ap- 
preciably after enterocyte-like differentiation of 
the HT29- 18 subclone. 
Decreased membrane fluidity during differentia- 
tion of human promyelocytic leukemia HL-60 cells 
[32] by dimethyl sulfoxide is also associated with 
reduced capacity of the differentiated granulocytic- 
like cells to generate CAMP after histamine HZ 
receptor activation [33]. The same observation was 
made during retinoic acid-induced monocytic dif- 
ferentiation of the human histiocytic lymphoma 
cell line U-937 [34,35]. 
Taken together, the present results and those for 
our studies of rat intestinal development [12,13] 
show that VIP receptor activity is indeed an in- 
dicator of intestinal cell maturation. Additional 
studies are needed to characterize further the fac- 
tor(s) responsible for the disturbing effects of 
enterocyte-like cell differentiation on VIP receptor- 
adenylate cyclase activities, and to assess their im- 
pact on the normal and tumoral development of 
the intestine. 
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